Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Shimuta, Ken ^a   Watanabe, Yuko ^b   Nakayama, Shu ichi ^a   Morita Ishihara, Tomoko ^a   Kuroki, Toshiro ^b   Unemo, Magnus ^c   Ohnishi, Makoto ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b KANAGAWA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^c Örebro University   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; PENICILLIN BINDING PROTEIN 2X; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; CEPHALOSPORIN DERIVATIVE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENE SEQUENCE; GENETIC SIMILARITY; GENETIC VARIABILITY; INFECTION CONTROL; INFECTION PREVENTION; JAPAN; MICROBIOLOGICAL EXAMINATION; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; NEISSERIA GONORRHOEAE; NEISSERIA GONORRHOEAE MULTIANTIGEN SEQUENCE TYPING; NONHUMAN; PENA GENE SEQUENCING; PHENOTYPE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; GONORRHEA; HIGH THROUGHPUT SEQUENCING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PREVALENCE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CEPHALOSPORINS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GONORRHEA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; MULTILOCUS SEQUENCE TYPING; NEISSERIA GONORRHOEAE; PREVALENCE; SEQUENCE ANALYSIS, DNA;

EID: 84941776218     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1110-x     Document Type: Article

References (33)

1. World Health Organization (WHO). Global incidence and prevalence of selected curable sexually transmitted infections - 2008. Geneva, Switzerland; 2012. Available at: http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf (Accessed: May 30, 2015).
2. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther. 2009;7:821-34.
3. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 2012;7:1401-22.
4. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: past, evolution, and future. Clin Microbiol Rev. 2014;27:587-613.
5. Lewis DA. The gonococcus fights back: is this time a knock out? Sex Transm Infect. 2010;86:415-21.
6. Ison CA. Antimicrobial resistance in sexually transmitted infections in the developed world: implications for rational treatment. Curr Opin Infect Dis. 2012;25:73-8.
7. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55:3538-45.
8. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 2013;309:163-70.
9. Lewis DA, Sriruttan C, Müller EE, Golparian D, Gumede L, Fick D, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum cephalosporin resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrobial Chemother. 2013;68:1267-70.
10. Read PJ, Limnios EA, McNulty A, Whiley D, Lahra MM. One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500mg ceftriaxone in Sydney. Australia Sex Health. 2013;10:460-2.
11. Chen YM, Stevens K, Tideman R, Zaia A, Tomita T, Fairley CK, et al. Failure of ceftriaxone 500mg to eradicate pharyngeal gonorrhoea. Australia J Antimicrob Chemother. 2013;68:1445-7.
12. Golparian D, Ohlsson A, Janson H, Lidbrink P, Richtner T, Ekelund O, et al. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Euro Surveill. 2014;19(30):20862.
13. Ohnishi M, Watanabe Y, Ono E, Takahashi C, Oya H, Kuroki T, et al. Spread of a chromosomal cefixime-resistant penA gene among different Neisseria gonorrhoeae lineages. Antimicrob Agents Chemother. 2010;54:1060-7.
14. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant N. gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56:1273-80.
15. Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67:1858-60.
16. Tanaka M, Nakayama H, Tunoe H, Egashira T, Kanayama A, Saika T, et al. A remarkable reduction in the susceptibility of Neisseria gonorrhoeae isolates to cephems and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. J Infect Chemother. 2002;8:81-6.
17. Ito M, Yasuda M, Yokoi S, Ito S, Takahashi Y, Ishihara S, et al. Remarkable increase in central Japan in 2001-2002 of Neisseria gonorrhoeae isolates with decreased susceptibility to penicillin, tetracycline, oral cephalosporins, and fluoroquinolones. Antimicrob Agents Chemother. 2004;48:3185-7.
18. Deguchi T, Yasuda M, Yokoi S, Ishida K, Ito M, Ishihara S, et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval. J Infect Chemother. 2003;9:35-9.
19. Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, et al. Threat to cefixime treatment of gonorrhea. Emerg Infect Dis. 2007;13:1275-7.
20. Janda WM, Gaydos CA. Neisseria. In: Murray P, Baron E, Jorgensen J, Landry ML, Pfaller M, editors. Manual of Clinical Microbiology. 9th ed. Washington, DC: ASM Press; 2007. p. 601-20.
21. Yamai S, Obara Y, Nikkawa T, Shimoda Y, Miyamoto Y. Preservation of Neisseria gonorrhoeae by the gelatin-disc method. Br J Vener Dis. 1979;55:90-3.
22. Clinical and Laboratory Standards Institute. 2014 Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
23. Ameyama S, Onodera S, Takahata M, Minami S, Maki N, Endo K, et al. Mosaic-like structure of penicillin-binding protein 2 gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime. Antimicrob Agents Chemother. 2002;46:3744-9.
24. Shimuta K, Unemo M, Nakayama S, Morita-Ishihara T, Dorin M, Kawahata T. Antimicrobial resistance and molecular typing of Neisseria gonorrhoeae isolates in Kyoto and Osaka, Japan in 2010-2012 - intensified surveillance after identification of the first high-level ceftriaxone resistant strain H041. Antimicrob Agents Chemother. 2013;57:5225-32.
25. Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother. 2007;51:3111-6.
26. Chisholm SA, Unemo M, Quaye N, Johansson E, Cole MJ, Ison CA, et al. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. Euro Surveill. 2013;18:ii=20358.
27. Lindberg R, Fredlund H, Nicholas R, Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: Association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother. 2007;51:2117-22.
28. Whiley DM, Goire N, Lambert SB, Ray S, Limnios EA, Nissen MD, et al. Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. J Antimicrob Chemother. 2010;65:1615-8.
29. Tomberg J, Unemo M, Davies C, Nicholas RA. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry. 2010;49:8062-70.
30. Pandori M, Barry PM, Wu A, Ren A, Whittington WL, Liska S, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco. California Antimicrob Agents Chemother. 2009;53:4032-4.
31. Bignell C, Unemo M, on behalf of the European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24:85-92.
32. Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61:590-4.
33. Powell AJ, Tomberg J, Deacon AM, Nicholas RA, Davies C. Crystal structures of penicillin-binding protein 2 from penicillin-susceptible and -resistant strains of Neisseria gonorrhoeae reveal an unexpectedly subtle mechanism for antibiotic resistance. J Biol Chem. 2009;284:1202-12.